Jane L Meisel1, David M Hyman2, Anjali Jotwani3, Qin Zhou3, Nadeem R Abu-Rustum4, Alexia Iasonos5, Malcolm C Pike3, Carol Aghajanian6. 1. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 6. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: aghajanc@mskcc.org.
Abstract
OBJECTIVE: Granulosa cell tumors (GCTs) are rare, and the role of chemotherapy in their management is not clearly defined. METHODS: We performed a retrospective cohort study of GCT patients diagnosed from January 1996 through June 2013 at the Memorial Sloan Kettering Cancer Center, comparing those who received adjuvant chemotherapy to those who did not. Differences between groups were assessed using the log-rank test. Statistical significance was set at p<0.05. RESULTS: Of 118 patients, 10 (8%) received adjuvant chemotherapy (1 [1%] of 103 stage I and 9 [60%] of 15 stage II-IV patients). Thirty-two patients (27%) experienced disease recurrence. Four patients had residual disease after initial surgery, and all received adjuvant chemotherapy; each recurred within 24.3 months (median PFS, 8.2 months). The time to first recurrence was longer in patients who did not receive adjuvant chemotherapy. For patients with recurrent disease, receiving chemotherapy after surgery for first recurrence did not seem to improve time to second recurrence versus surgery alone (HR 0.98; p=0.965). Additionally, 12 patients (10%) had a previous diagnosis of breast cancer-an incidence rate 3.22 times higher than Surveillance, Epidemiology, and End Results (SEER) data predicts (p<0.001). CONCLUSIONS: Although the numbers were small, in this analysis chemotherapy was not found to improve the recurrence-free interval of patients with GCTs, a finding that requires prospective validation. Residual disease after surgery was associated with poor prognosis. Finally, there was a significantly higher than expected incidence of antecedent breast cancer in this population, an association that deserves further exploration.
OBJECTIVE:Granulosa cell tumors (GCTs) are rare, and the role of chemotherapy in their management is not clearly defined. METHODS: We performed a retrospective cohort study of GCT patients diagnosed from January 1996 through June 2013 at the Memorial Sloan Kettering Cancer Center, comparing those who received adjuvant chemotherapy to those who did not. Differences between groups were assessed using the log-rank test. Statistical significance was set at p<0.05. RESULTS: Of 118 patients, 10 (8%) received adjuvant chemotherapy (1 [1%] of 103 stage I and 9 [60%] of 15 stage II-IV patients). Thirty-two patients (27%) experienced disease recurrence. Four patients had residual disease after initial surgery, and all received adjuvant chemotherapy; each recurred within 24.3 months (median PFS, 8.2 months). The time to first recurrence was longer in patients who did not receive adjuvant chemotherapy. For patients with recurrent disease, receiving chemotherapy after surgery for first recurrence did not seem to improve time to second recurrence versus surgery alone (HR 0.98; p=0.965). Additionally, 12 patients (10%) had a previous diagnosis of breast cancer-an incidence rate 3.22 times higher than Surveillance, Epidemiology, and End Results (SEER) data predicts (p<0.001). CONCLUSIONS: Although the numbers were small, in this analysis chemotherapy was not found to improve the recurrence-free interval of patients with GCTs, a finding that requires prospective validation. Residual disease after surgery was associated with poor prognosis. Finally, there was a significantly higher than expected incidence of antecedent breast cancer in this population, an association that deserves further exploration.
Authors: A Fishman; A P Kudelka; D Tresukosol; C L Edwards; R S Freedman; A L Kaplan; R E Girtanner; J J Kavanagh Journal: J Reprod Med Date: 1996-06 Impact factor: 0.142
Authors: In Ho Lee; Chel Hun Choi; Dae Gy Hong; Jae Yun Song; Young Jae Kim; Kyung Tai Kim; Kyu Wan Lee; Il Soo Park; Duk Soo Bae; Tae Jin Kim Journal: J Gynecol Oncol Date: 2011-09-28 Impact factor: 4.401
Authors: Powel Crosley; Anniina Farkkila; Adrianne L Jenner; Chloé Burlot; Olivia Cardinal; Kyle G Potts; Kate Agopsowicz; Marjut Pihlajoki; Markku Heikinheimo; Morgan Craig; Yangxin Fu; Mary M Hitt Journal: Int J Mol Sci Date: 2021-04-29 Impact factor: 5.923
Authors: Anton Oseledchyk; Renee L Gennarelli; Mario M Leitao; Carol A Aghajanian; Alexia Iasonos; Oliver Zivanovic; Dmitriy Zamarin Journal: Cancer Med Date: 2018-04-17 Impact factor: 4.452
Authors: Dimitrios Nasioudis; Emily M Ko; Ashley F Haggerty; Robert L Giuntoli; Robert A Burger; Mark A Morgan; Nawar A Latif Journal: Gynecol Oncol Rep Date: 2019-04-17
Authors: Joline F Roze; Joachim Kutzera; Wouter Koole; Margreet G E M Ausems; Kristi Engelstad; Jurgen M J Piek; Cor D de Kroon; René H M Verheijen; Gijs van Haaften; Ronald P Zweemer; Glen R Monroe Journal: Cancers (Basel) Date: 2021-05-18 Impact factor: 6.639